Oncology 101: A Hematology and Oncology Primer for Advanced Practice Providers - Enduring


The demand for cancer care is expected to grow 40% over the next six years and ASCO is projecting a shortage of more than 2,200 oncologists by 2025. To meet the cancer care needs of patients, advanced practice providers (APPs), whose education and training is focused on health promotion, disease prevention, and primary care medical management, have increasingly been sought to fill the shortage. However, many APPs have little background or training in oncology. As a result, oncology practices need to provide new staff with an onboarding program that helps to establish a working baseline level of knowledge of hematology and oncology.

To help APPs prepare for a new career in the specialty of oncology, Horizon CME in partnership with APAO has developed “Oncology 101: A Hematology and Oncology Primer for Advanced Practice Providers”. In this activity, clinicians will gain a basic understanding of cancer therapies, benign and malignant hematologic disorders, solid malignancies, supportive care strategies, genetics, molecular testing, and more. Participation in this activity will help pave the way for APPs to provide support and care to cancer patients as part of the multidisciplinary oncology care team. 


 (01) Introduction to Malignant Hematology (1.75 CE)


  • Define the clinical manifestations, diagnostic modalities, and basic treatment strategies for the common hematologic malignancies (ALL, AML, MDS, MF, CLL, CML, HL, NHL, MM, and MGUS)
  • Describe the sub-types of non-Hodgkin lymphoma, including defining characteristics
  • Summarize the impact of molecular and genetic testing in hematologic malignancies

Jennie M. Goble, PA-C – Mayo Clinic (35 minutes) - Acute lymphocytic leukemia (ALL), Acute myelogenous leukemia (AML), Myelodysplastic syndromes, and Myelofibrosis 

Amy Goodrich, RN, MSN, CRNP – Johns Hopkins (20 minutes) - Chronic lymphocytic leukemia (CLL) and Chronic myelogenous leukemia (CML)

Bruce Christensen, PA-C – UT Health San Antonio (20 minutes) - Hodgkin lymphoma and Non-hodgkin lymphoma

Beth Faiman, PhD, CNP – Cleveland Clinic (30 minutes) - Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), and Amyloidosis and Waldenstroms

(02) Introduction to Benign Hematology (1.25 CE)


  • Review the diagnosis and management of common red cell, white cell, and platelet disorders 
  • Describe strategies for prophylaxis and management of coagulopathies 
  • Outline updated treatment for benign hematologic conditions

Beth Faiman, PhD, CNP – Cleveland Clinic (35 minutes) - Anemia, Idiopathic and Immune TP (ITP), and Essential thrombocytosis

Lauren Imboden, PA-C – Atrium Health Wake Forest Baptist (40 minutes) - Polycythemia, Hemophilia, and Coagulopathies (factor V leiden, VTE)

(03) Introduction to Solid Malignancies (1.50 CE)


  • Define the clinical manifestations, diagnostic modalities, and basic treatment strategies for the common solid malignancies (breast CA, lung cancer, colorectal cancer, prostate cancer, and bladder cancer)
  • Describe the risk factors and molecular basis for solid tumors
  • Summarize the role of molecular and genetic testing in management of solid malignancies

Kristi Kay Orbaugh, NP – Community Hospital Oncology Physicians (25 minutes) - Breast Cancer

Beth Sandy, MSN, CRNP – Penn Medicine (25 minutes) - Lung Cancer

Kathleen Boyle, PA-C – Dana Farber (15 minutes) - Colorectal cancer

Victoria Wong, PA-C – Fox Chase Cancer Center (25 minutes) - Prostate and bladder cancer

(04) Chemotherapy Review (0.75 CE)

» Sandra Cuellar, PharmD, BCOP – University of Illinois Chicago


  • Describe the rationale of combination chemotherapy
  • List the major chemotherapy drug classifications and their mechanism of action
  • Identify the major toxicities associated with chemotherapy

(05) Targeted Therapies (0.50 CE)

» Jennifer Murphy, PharmD, BCOP – UC Davis


  • Review the mechanism of action for targeted therapies
  • Outline the indications for currently available targeted therapies
  • Recognize common side-effects associated with targeted therapies

(06) Basics of Radiation Oncology (0.50 CE)

Maitry Patel, PA-C – University Health Network, Toronto


  • Review the role and history of radiation therapy (RT)
  • Discuss the physical and biological basis for RT
  • Outline the clinical applications of RT in the management of cancer
  • Describe the RT process including simulation, treatment planning, and delivery
  • Identify the types of RT available

(07) Immunotherapies (0.50 CE)

Joslyn Rudoni, PharmD, BCOP – Cleveland Clinic Taussig Cancer Center


  • Review the mechanism of action for targeted therapies
  • Outline the indications for currently available targeted therapies
  • Recognize common side-effects associated with targeted therapies

(08) Supportive Care (1.00 CE)

Laura J. Zitella, MS, RN, ACNP-BC, AOCN – UCSF


  • Describe standard preventive medications for acute and delayed emesis based on the emetic risk of the anticancer regimen
  • Develop a diagnostic approach to differentiate iron deficiency anemia, anemia of inflammation, cancer-related anemia and cancer treatment-related anemia
  • Identify febrile neutropenia and implement evidence-based management strategies
  • Discuss prevention and treatment of oral and gastrointestinal mucosal injury
  • Identify strategies for the management of infusion reactions to systemic anticancer therapy

(09) CAR-T Cell Therapy (0.50 CE)

Sherry Adkins, RN, MSN, ANP-C – MD Anderson


  • Describe the mechanisms of action and clinical indications for CAR T-cell therapy.
  • Apply strategies to appropriately assess and manage the potential acute and long-term toxicities associated with CAR T-cell therapy.

(10) Oncologic Emergencies (0.75 CE)

Brenda Shelton, DNP, APRN-CNS, RN, CCRN, AOCN – Johns Hopkins


  • Explain the risk factors and interventions for febrile neutropenia and sepsis and apply them to patient management.
  • Describe the pathophysiology for tumor lysis syndrome and list the risk factors and appropriate interventions.
  • Recognize and provide appropriate interventions for infusion reactions, hypersensitivity reactions, and cytokine release syndrome.
  • State the common oncology emergencies for immunotherapy and identify them in patients.
  • List the signs, symptoms, and interventions for immune induced pneumonitis, endocrinopathies, and colitis.

(11) Stem Cell Transplant (0.50 CE)

Linda M. Perry, PA-C – Penn Medicine


  • Identify the types of stem cell transplant and the conditions in which it is used to treat
  • List conditioning regimens used for stem cell transplant
  • Describe the pathophysiology, presenting symptoms and treatment of acute and chronic GVHD

(12) Palliative Care (0.50 CE)



  • Define palliative care and hospice.
  • Identify strategies for integrating palliative care into oncology practices.


Target Audience

Oncology 101 is developed with and for advanced practice providers including PA, NP, PharmD and RN.

As part of the multidisciplinary team in the care of cancer patients, students, physicians, and other healthcare professionals involved in the management of cancer patients are also welcome to attend

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  1. Describe the presentation, evaluation, and treatment of common solid and hematologic malignancies
  2. Recognize the presentation, evaluation, and treatment of common benign hematologic disorders 
  3. Summarize the role of genetics and molecular testing in cancer care 
  4. Compare and contrast the various types of cancer treatment including stem cell transplant, chemotherapy, targeted therapies, radiotherapy, and immunotherapy
  5. Identify and appropriately manage common oncologic emergencies
  6. Outline the role of palliative care and effectively incorporate it into oncology practice
APAO is proud to offer FREE access to Oncology 101 as an APAO Member Benefit. Click here to fill out this quick form or to join for your member code for free access to Oncology 101.  


Horizon CME designates this activity for a maximum of 10.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

And for more CME opportunities developed by APPs, for APPs, click HERE!